Hematologic toxicities associated with intravenous immunoglobulin therapy.

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Intravenous immunoglobulin (IVIG) is a widely used immunomodulating agent for various conditions.
• While generally safe and effective, IVIG can cause adverse effects.
• Hematologic complications are a significant concern associated with IVIG therapy.

Purpose of the Study:

• To summarize hematologic toxicities linked to IVIG therapy.
• To describe strategies for identifying and managing these adverse events.
• To enhance clinician awareness of IVIG-associated hematologic risks.

Main Methods:

• Literature review of reported hematologic toxicities from IVIG therapy.
• Analysis of adverse event profiles in published studies.
• Synthesis of identification and management strategies.

Main Results:

• IVIG is associated with hematologic complications including hemolytic anemia, leukopenia, neutropenia, monocytopenia, and disseminated intravascular coagulation.
• Changes in blood rheology and thrombotic events (venous and arterial) can occur.
• Clinicians must be aware of these potential adverse events.

Conclusions:

• IVIG therapy carries risks of significant hematologic adverse events.
• Prompt identification and appropriate management are crucial for patient safety.
• Understanding these toxicities is essential for effective clinical use of IVIG.